At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ERYP Erytech Pharma S.A.
Not Yet Opened 06-28 16:00:00 EDT
0.7800
+0.0000
0.00%
High0.7800Low0.7800Vol0.00
Open0.7800D1 Closing0.7800Amplitude0.00%
Mkt Cap26.61MTradable Cap24.01MTotal Shares34.12M
T/O2.73KT/O Rate0.00%Tradable Shares30.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
T-Reuters  ·  2023-06-15
Erytech Announces That The Commercial Court Has Rejected Akkadian's Request To Postpone The Vote On The Merger With Pherecydes Pharma
Erytech Pharma Reported Cash And Cash Equivalents Of $33.7M At End Of March 2023
Benzinga  ·  2023-05-09
Erytech Pharma Reported Cash And Cash Equivalents Of $33.7M At End Of March 2023
Press Release: ERYTECH Provides Business and Financial Update for the First Quarter of 2023
Dow Jones  ·  2023-05-09
Press Release: ERYTECH Provides Business and Financial Update for the First Quarter of 2023

Introduction

Company Name.
Erytech Pharma S.A.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Issue price:
--